demonstrates consistently low stent thrombosis rates in over 18,000 patients across 9 studies#
Boston Scientific is committed to providing updated medical information on its products, to healthcare professionals, which is in compliance with Indian regulations. All product related information made available on this website are for the reference of licensed healthcare professionals only. All consumers or patients are advised to consult their doctor or physician for advice on medical devices or any health related matters. Consumers or patients who use this website and rely on any information herein do so at their own risk. In no case shall Boston Scientific India Private Limited, or any of its affiliates, directors or employees be liable to any person or entity for any damages or losses resulting either directly or indirectly from the access of information provided in this website.
By clicking “I am a Physician” you confirm your understanding and acceptance of the statements of this disclaimer.
Lowest ST rate in statistically more complex patients
Syntax II Trial
The SYNTAX II Trial utilizing SYNERGYTM Stent, physiological assessment, IVUS guidance, and contemporary state-of-the-art PCI techniques, demonstrated equivalent outcomes to CABG in patients with three-vessel disease at 2-years3.